… If the current trend continues, the cases of Alzheimer's disease will increase four times in the
… distribution of the pathological changes in the neocortex in alzheimer disease. Proc. Natl. …

… , the phase of MCI ends with a marked decline in cognitive function as the disease pathology
… Is the Subject Area "Alzheimer's disease diagnosis and management" applicable to this …

… Structural abnormalities in these regions represent a marker of AD pathology, so-called “AD-signature”
[134,135]. The regions have been previously described as the Default Mode …

… tau pathology at different stages of AD. Although we identified commonly regulated proteins
and pathways during disease … In addition, a distinct proteomic signature was found between …

… decline in Alzheimer’s disease (AD). However, the molecular signatures that distinguish …
identified both shared and cell-type-specific signatures. NFT-bearing neurons shared a marked …

… disease progression in the brain remain largely unknown. To better understand the pathological
… , and atrophy correlated with severity of brain Aβ pathology, tauopathy, and atrophy, and …

… a signature of cortical regions of interest preferentially affected by Alzheimer disease (AD)
pathology … Since late-onset Alzheimer disease (LOAD) participants tend to have age-related …

… We identified hypometabolism signatures for each clinical atypical variant within the AD …
paradigm of neurodegenerative disease, positing that the pathology associated with these …

… Alzheimer disease (AD) diagnosis. Our results indicate that the serum microRNA signature
… Alzheimer disease (AD) 6 is the most common form of dementia with increasing prevalence …

… signature. In steps 3 and 4, we tested associations between the incipient AD proteomic
signature and both AD pathology … pathology. In step 6b, we validated the incipient AD proteomic …